全文获取类型
收费全文 | 263600篇 |
免费 | 8269篇 |
国内免费 | 627篇 |
专业分类
耳鼻咽喉 | 3656篇 |
儿科学 | 9390篇 |
妇产科学 | 7244篇 |
基础医学 | 34271篇 |
口腔科学 | 7390篇 |
临床医学 | 21270篇 |
内科学 | 49346篇 |
皮肤病学 | 5773篇 |
神经病学 | 17980篇 |
特种医学 | 13187篇 |
外国民族医学 | 103篇 |
外科学 | 39437篇 |
综合类 | 1668篇 |
一般理论 | 32篇 |
预防医学 | 22105篇 |
眼科学 | 5921篇 |
药学 | 18438篇 |
3篇 | |
中国医学 | 309篇 |
肿瘤学 | 14973篇 |
出版年
2021年 | 1304篇 |
2019年 | 1247篇 |
2018年 | 5080篇 |
2017年 | 5060篇 |
2016年 | 4542篇 |
2015年 | 6156篇 |
2014年 | 6097篇 |
2013年 | 6124篇 |
2012年 | 13790篇 |
2011年 | 9053篇 |
2010年 | 4525篇 |
2009年 | 5794篇 |
2008年 | 5912篇 |
2007年 | 7028篇 |
2006年 | 7186篇 |
2005年 | 15119篇 |
2004年 | 16509篇 |
2003年 | 11987篇 |
2002年 | 7184篇 |
2001年 | 5557篇 |
2000年 | 2994篇 |
1999年 | 6951篇 |
1998年 | 1275篇 |
1992年 | 7460篇 |
1991年 | 7605篇 |
1990年 | 7876篇 |
1989年 | 7434篇 |
1988年 | 6974篇 |
1987年 | 6737篇 |
1986年 | 6429篇 |
1985年 | 5770篇 |
1984年 | 4146篇 |
1983年 | 3426篇 |
1982年 | 1520篇 |
1980年 | 1231篇 |
1979年 | 4247篇 |
1978年 | 2723篇 |
1977年 | 2129篇 |
1976年 | 1859篇 |
1975年 | 2775篇 |
1974年 | 3417篇 |
1973年 | 3051篇 |
1972年 | 3043篇 |
1971年 | 2970篇 |
1970年 | 2782篇 |
1969年 | 2702篇 |
1968年 | 2460篇 |
1967年 | 2343篇 |
1966年 | 2072篇 |
1965年 | 1259篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
4.
5.
6.
Esin Benli Küçük Ercan Kaydok Kürsad Ramazan Zor Gamze Yıldırım Biçer 《Topics in stroke rehabilitation》2020,27(8):630-635
ABSTRACT Objective: Dry eye is reported to be associated with several neurological diseases. The aim of this study is to evaluate the patients with hemiplegia after stroke for dry eye and compare their results with a control group. Materials and methods: Forty-five patients with hemiplegia and 45 individuals as the control group were included in the study. Tear function tests (Schirmer and tear breakup time) and a dry eye questionnaire for dry eye symptoms (ocular surface disease index) were performed and the results of the two groups were compared. Results: Schirmer test results were significantly lower in the post-stroke hemiplegia group compared to the control group (11.3 ± 8.2 mm and 20.6 ± 11.6 mm, respectively, p < .001). Tear breakup time results were significantly lower in the post-stroke hemiplegia group compared to the control group (7.9 ± 3.1 s and 12.1 ± 4.3 s, respectively, p < .001). Ocular surface disease index scores were not significantly different between hemiplegia and control groups (21.6 ± 20.0 and 19.8 ± 13.9, respectively, p = .635). Schirmer scores lower than 10 mm (60% and 30%, p < .001) and tear breakup time results lower than 10 s (65.6% and 28.9%, p < .001) were also higher in the hemiplegia group compared to control group. Conclusion: We found lower Schirmer test and tear breakup time results and similar OSDI scores in hemiplegia patients compared to controls. Hemiplegia patients may have dry eye without typical symptoms. This should be taken into consideration in the follow-up and rehabilitation of post-stroke hemiplegia patients. 相似文献
7.
8.
9.
10.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献